Exercise training normalizes mitochondrial respiratory capacity within the striatum of the R6/1 model of Huntington's disease.

Herbst EA, Holloway GP.

Neuroscience. 2015 Sep 10;303:515-23. doi: 10.1016/j.neuroscience.2015.07.025.

Biological Perspectives: Huntington's Disease.

Kowalski PC, Belcher DC, Keltner NL, Dowben JS.

Perspect Psychiatr Care. 2015 Jul;51(3):157-61. doi: 10.1111/ppc.12121. Review. No abstract available.

Genetic deletion of the Histone Deacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease.

Ragot A, Pietropaolo S, Vincent J, Delage P, Zhang H, Allinquant B, Leinekugel X, Fischer A, Cho YH.

Brain Behav. 2015 Sep;5(9):e00361. doi: 10.1002/brb3.361.

Donor-Specific Anti-HLA Antibodies in Huntington's Disease Recipients of Human Fetal Striatal Grafts.

Porfirio B, Paganini M, Mazzanti B, Bagnoli S, Bucciantini S, Ghelli E, Nacmias B, Putignano AL, Rombolà G, Saccardi R, Lombardini L, Di Lorenzo N, Vannelli GB, Gallina P.

Cell Transplant. 2015;24(5):811-7. doi: 10.3727/096368913X676222.

Chorea associated with high titers of antiphospholipid antibodies in the absence of antiphospholipid antibody syndrome.

Safarpour D, Buckingham S, Jabbari B.

Tremor Other Hyperkinet Mov (N Y). 2015 Feb 13;5:294. doi: 10.7916/D8DB80M9.

Behavioral and neurophysiological evidence for the enhancement of cognitive control under dorsal pallidal deep brain stimulation in Huntington's disease.

Beste C, Mückschel M, Elben S, J Hartmann C, McIntyre CC, Saft C, Vesper J, Schnitzler A, Wojtecki L.

Brain Struct Funct. 2015 Jul;220(4):2441-8. doi: 10.1007/s00429-014-0805-x.

Delayed Cell Cycle Progression in STHdh(Q111)/Hdh(Q111) Cells, a Cell Model for Huntington's Disease Mediated by microRNA-19a, microRNA-146a and microRNA-432.

Das E, Jana NR, Bhattacharyya NP.

Microrna. 2015;4(2):86-100.

Three Huntington's Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes.

Jacquet L, Neueder A, Földes G, Karagiannis P, Hobbs C, Jolinon N, Mioulane M, Sakai T, Harding SE, Ilic D.

PLoS One. 2015 May 20;10(5):e0126860. doi: 10.1371/journal.pone.0126860.

Inhibition of Aggregation of Mutant Huntingtin by Nucleic Acid Aptamers In Vitro and in a Yeast Model of Huntington's Disease.

Chaudhary RK, Patel KA, Patel MK, Joshi RH, Roy I.

Mol Ther. 2015 Dec;23(12):1912-26. doi: 10.1038/mt.2015.157.

Factor analysis of the hospital anxiety and depression scale among a Huntington's disease population.

Dale M, Maltby J, Martucci R, Shimozaki S; REGISTRY investigators of the European Huntington's Disease Network..

Mov Disord. 2015 Dec;30(14):1954-60. doi: 10.1002/mds.26419.

Prevalence of Huntington's disease gene CAG trinucleotide repeat alleles in patients with bipolar disorder.

Ramos EM, Gillis T, Mysore JS, Lee JM, Alonso I, Gusella JF, Smoller JW, Sklar P, MacDonald ME, Perlis RH.

Bipolar Disord. 2015 Jun;17(4):403-8. doi: 10.1111/bdi.12289.

Lead optimization toward proof-of-concept tools for Huntington's disease within a 4-(1H-pyrazol-4-yl)pyrimidine class of pan-JNK inhibitors.

Wityak J, McGee KF, Conlon MP, Song RH, Duffy BC, Clayton B, Lynch M, Wang G, Freeman E, Haber J, Kitchen DB, Manning DD, Ismail J, Khmelnitsky Y, Michels P, Webster J, Irigoyen M, Luche M, Hultman M,

J Med Chem. 2015 Apr 9;58(7):2967-87. doi: 10.1021/jm5013598.

Hashimoto's Encephalopathy Presenting with Chorea.

Sharan A, Sengupta S, Mukhopadhyay S, Ghosh B.

J Assoc Physicians India. 2015 Sep;63(9):83-4.

A New VMAT-2 Inhibitor NBI-641449 in the Treatment of Huntington Disease.

Chen S, Zhang XJ, Xie WJ, Qiu HY, Liu H, Le WD.

CNS Neurosci Ther. 2015 Aug;21(8):662-71. doi: 10.1111/cns.12425.

[Molecular therapeutic strategies for Huntington's disease].

Milewski M, Hoffman-Zacharska D, Ball J.

Postepy Biochem. 2015;61(1):18-24. Review. Polish.